News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zocere, Inc. Expands Development Portfolio, Licenses Neuroprotectant Technology For Stroke And Other Brain Trauma From STC.UNM


3/10/2014 8:51:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Zocere, Inc., has signed a licensing agreement for a novel neuroprotectant treatment for ischemic stroke and other neurological disorders from STC.UNM, the University of New Mexico’s technology transfer and economic development organization. Zocere is a New Mexico-based pharmaceutical company developing drug-based treatments for neurological diseases, with the most compelling data to date for the treatment of stroke. Currently, there are few treatment options for blood clot-induced ischemic stroke, which accounts for 87 percent of strokes. Those on the market are little used and have risks associated with their use. Zocere’s newly licensed STEP protein, a biologic that is a cell-permeable, recombinant peptide, shows promise as a potent “brain saving” drug when administered post stroke.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES